1.The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients.
Soyi LIM ; Yun Hwan KIM ; Kwang Beom LEE ; Jong Min LEE
Journal of Gynecologic Oncology 2018;29(5):e72-
		                        		
		                        			
		                        			OBJECTIVE: To determine whether drospirenone/estradiol (DRSP/E2) has an adverse effect on clinical outcomes in surgically staged International Federation of Gynecology and Obstetrics (FIGO) stage I/II endometrial cancer (EC) patients. METHODS: In a retrospective case-controlled study, 58 women with EC who had received DRSP/E2 postoperatively were compared with 116 women who had not. And, oncologic safety of postoperative hormone therapy with DRSP/E2 in EC survivors were compared between the 2 groups after propensity score matching using a logistic regression model. RESULTS: The median ages were 47.7 years and 53.6 years for the study and the control groups, respectively (p < 0.001). The study group had similar parity (p = 0.71), lower body mass index (p = 0.03) and more premenopausal women (p < 0.001) than the control group. The stages were completely matched. The grades (p = 0.42), lymphovascular space invasion (p = 0.23), preoperative cancer antigen 125 (CA 125) level (p = 0.89), and hormone receptor status (p = 0.07) were similar in both groups. The median tumor diameter was statistically larger in the study group than in the control group (p < 0.001). Both group received similar adjuvant therapy (p = 0.80). In the propensity matching, only hormone receptor status was significantly different (p = 0.03). In the univariate analysis, only stage was significantly associated with disease-free survival (DFS) and there was no variable associated with overall survival (OS). And, there was no significant factor identified in multivariate analysis. The difference in the DFS (p = 0.63) and in the OS (p = 0.32) was not significant. The same results were obtained after propensity score matching. CONCLUSION: Postoperative hormone therapy with DRSP/E2 in EC survivors did not increase recurrence or the death rate.
		                        		
		                        		
		                        		
		                        			Body Mass Index
		                        			;
		                        		
		                        			Case-Control Studies
		                        			;
		                        		
		                        			Disease-Free Survival
		                        			;
		                        		
		                        			Endometrial Neoplasms*
		                        			;
		                        		
		                        			Estradiol
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Gynecology
		                        			;
		                        		
		                        			Hormone Replacement Therapy
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Logistic Models
		                        			;
		                        		
		                        			Mortality
		                        			;
		                        		
		                        			Multivariate Analysis
		                        			;
		                        		
		                        			Obstetrics
		                        			;
		                        		
		                        			Parity
		                        			;
		                        		
		                        			Propensity Score
		                        			;
		                        		
		                        			Recurrence
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Survivors
		                        			
		                        		
		                        	
2.Factors associated with parametrial involvement in patients with stage IB1 cervical cancer: Who is suitable for less radical surgery?
Seung Ho LEE ; Kyoung Joo CHO ; Mi Hyang KO ; Hyun Yee CHO ; Kwang Beom LEE ; Soyi LIM
Obstetrics & Gynecology Science 2018;61(1):88-94
		                        		
		                        			
		                        			OBJECTIVE: To detect the possible clinicopathologic factors associated with parametrial involvement in patients with stage IB1 cervical cancer and to identify a cohort of patients who may benefit from less radical surgery. METHODS: We retrospectively reviewed 120 patients who underwent radical hysterectomy and pelvic lymphadenectomy as treatment for stage IB1 cervical cancer. RESULTS: Overall, 18 (15.0%) patients had parametrial tumor involvement. Tumor size larger than 2 cm, invasion depth greater than 1 cm, presence of lymphovascular space involvement (LVSI), corpus involvement, and positive lymph nodes were statistically associated with parametrial involvement. Multivariate analysis for other factors showed invasion depth >1 cm (P=0.029), and corpus involvement (P=0.022) were significantly associated with parametrial involvement. A subgroup with tumor size smaller than 2 cm showed no parametrial involvement, regardless of invasion depth or presence of LVSI. CONCLUSION: Tumor size smaller than 2 cm showed no parametrial involvement, regardless of invasion depth or presence of LVSI. Invasion depth >1 cm and corpus involvement were significantly associated with parametrial involvement in multivariate analysis. These finding may suggest that tumor size may a strong predictor of parametrial involvement in International Federation of Gynecology and Obstetrics stage IB1 cervical cancer, which can be used to select a subgroup population for less radical surgery.
		                        		
		                        		
		                        		
		                        			Cohort Studies
		                        			;
		                        		
		                        			Gynecology
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hysterectomy
		                        			;
		                        		
		                        			Lymph Node Excision
		                        			;
		                        		
		                        			Lymph Nodes
		                        			;
		                        		
		                        			Multivariate Analysis
		                        			;
		                        		
		                        			Obstetrics
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Uterine Cervical Neoplasms
		                        			
		                        		
		                        	
3.Influence of previous abdominal surgery on clinical outcomes of patients undergoing total laparoscopic hysterectomy.
Eun Seok SEO ; Seung Ho LEE ; Seung Joo CHON ; Sun Young JUNG ; Yoon Jin CHO ; Soyi LIM
Obstetrics & Gynecology Science 2018;61(3):379-385
		                        		
		                        			
		                        			OBJECTIVE: To evaluate the potential effects of previous abdominal surgery on post-operative outcome and incidence of complications after total laparoscopic hysterectomy (TLH). METHODS: Between June 2008 and December 2016, 331 patients who underwent TLH were retrospectively reviewed. Participating patients were divided into 2 groups according to previous abdominal surgery. We compared the 2 groups based on estimated blood loss, operation time, hospital stay, surgery-related complications, and conversion to laparotomy rates. RESULTS: Group 1 included patients without a history of abdominal surgery (n=186), group 2 included patients with a history of abdominal surgery (n=145). The complication rate was 3.2% in group 1 and 2.8% in group 2. Other post-operative outcome and complications such as estimated blood loss, hospital stay and conversion to laparotomy rates did not differ significantly between groups. Adhesiolysis was significantly more common in group 2 (P < 0.001) and operation time was significantly longer in the group 2 (P=0.004). The rate of conversion to laparotomy was higher in group 2, but this difference was not significant (P=0.115). Group 2 patients were divided into subgroups according to the number of surgery. In subgroups analysis of group 2, there were 70 patients who had one previous abdominal surgery and 75 patients who had 2 or more previous surgeries. Moreover, there were significant differences in adhesiolysis (P=0.004) and conversion to laparotomy (P=0.034). There were no significant differences in other complications observed upon subgroup analysis. CONCLUSION: TLH can be conducted successfully regardless of previous abdominal surgery. Patients with previous abdominal surgery are suitable and feasible candidates for TLH.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hysterectomy*
		                        			;
		                        		
		                        			Incidence
		                        			;
		                        		
		                        			Laparoscopy
		                        			;
		                        		
		                        			Laparotomy
		                        			;
		                        		
		                        			Length of Stay
		                        			;
		                        		
		                        			Postoperative Complications
		                        			;
		                        		
		                        			Retrospective Studies
		                        			
		                        		
		                        	
4.Use of a cognitive computing system for treatment of cervical cancer.
Journal of Gynecologic Oncology 2017;28(5):e67-
		                        		
		                        			
		                        			No abstract available.
		                        		
		                        		
		                        		
		                        			Uterine Cervical Neoplasms*
		                        			
		                        		
		                        	
5.The influence of number of high risk factors on clinical outcomes in patients with early-stage cervical cancer after radical hysterectomy and adjuvant chemoradiation.
Soyi LIM ; Seok Ho LEE ; Kwang Beom LEE ; Chan Yong PARK
Obstetrics & Gynecology Science 2016;59(3):184-191
		                        		
		                        			
		                        			OBJECTIVE: The purpose of this study was to evaluate the prognosis according to the number of high risk factors in patients with high risk factors after radical hysterectomy and adjuvant chemoradiation therapy for early stage cervical cancer. METHODS: Clinicopathological variables and clinical outcomes of patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB1 to IIA cervical cancer who had one or more high risk factors after radical hysterectomy and adjuvant chemoradiation therapy were retrospectively analyzed. Patients were divided into two groups according to the number of high risk factors (group 1, single high risk factor; group 2, two or more high risk factors). RESULTS: A total of 93 patients were enrolled in the present study. Forty nine out of 93 (52.7%) patients had a single high risk factor, and 44 (47.3%) had two or more high risk factors. Statistically significant differences in stage and stromal invasion were observed between group 1 and group 2. However, age, histology, tumor size, and lymphovascular space invasion did not differ significantly between the groups. Distant recurrence occurred more frequently in group 2, and the probability of recurrence and death was higher in group 2. CONCLUSION: Patients with two or more high risk factors had worse prognosis in early stage cervical cancer. For these patients, consideration of new strategies to improve survival may be worthwhile. Conduct of further clinical trials is warranted for development of adjuvant treatment strategies individualized to each risk group.
		                        		
		                        		
		                        		
		                        			Gynecology
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hysterectomy*
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Recurrence
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Risk Factors*
		                        			;
		                        		
		                        			Uterine Cervical Neoplasms*
		                        			
		                        		
		                        	
6.Erratum to: Sclerosing Stromal Tumor of the Ovary in Postmenopausal Women: A Report of Two Cases.
Chae Min LEE ; Soyi LIM ; Hyun Yi CHO ; Ji Sung LEE ; Jin Woo SHIN
Journal of Menopausal Medicine 2015;21(3):175-175
		                        		
		                        			
		                        			In this article, on page 115, the title has been spelled incorrectly in this article.
		                        		
		                        		
		                        		
		                        	
7.A Clinical Analysis of Brain Metastasis in Gynecologic Cancer: A Retrospective Multi-institute Analysis.
Young Zoon KIM ; Jae Hyun KWON ; Soyi LIM
Journal of Korean Medical Science 2015;30(1):66-73
		                        		
		                        			
		                        			This study analyzes the clinical characteristics of the brain metastasis (BM) of gynecologic cancer based on the type of cancer. In addition, the study examines the factors influencing the survival. Total 61 BM patients of gynecologic cancer were analyzed retrospectively from January 2000 to December 2012 in terms of clinical and radiological characteristics by using medical and radiological records from three university hospitals. There were 19 (31.1%) uterine cancers, 32 (52.5%) ovarian cancers, and 10 (16.4%) cervical cancers. The mean interval to BM was 25.4 months (21.6 months in ovarian cancer, 27.8 months in uterine cancer, and 33.1 months in cervical cancer). The mean survival from BM was 16.7 months (14.1 months in ovarian cancer, 23.3 months in uterine cancer, and 8.8 months in cervical cancer). According to a multivariate analysis of factors influencing survival, type of primary cancer, Karnofsky performance score, status of primary cancer, recursive partitioning analysis class, and treatment modality, particularly combined therapies, were significantly related to the overall survival. These results suggest that, in addition to traditional prognostic factors in BM, multiple treatment methods such as neurosurgery and combined chemoradiotherapy may play an important role in prolonging the survival for BM patients of gynecologic cancer.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Brain/*pathology
		                        			;
		                        		
		                        			Brain Neoplasms/*mortality/*secondary/therapy
		                        			;
		                        		
		                        			Chemoradiotherapy
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Genital Neoplasms, Female/*mortality/pathology/therapy
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Multivariate Analysis
		                        			;
		                        		
		                        			Ovarian Neoplasms/mortality/pathology/therapy
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Uterine Cervical Neoplasms/mortality/pathology/therapy
		                        			;
		                        		
		                        			Uterine Neoplasms/mortality/pathology/therapy
		                        			;
		                        		
		                        			Young Adult
		                        			
		                        		
		                        	
8.Sclerosing Sromal Tumor of the Ovary in Postmenopausal Women: A Report of Two Cases.
Chae Min LEE ; Soyi LIM ; Hyun Yi CHO ; Ji Sung LEE ; Jin Woo SHIN
Journal of Menopausal Medicine 2015;21(2):115-119
		                        		
		                        			
		                        			Sclerosing stromal tumor (SST) was first delineated as a distinct ovarian sex cord stromal tumor in 1973 by Chalvardjian and Scully. It is a benign neoplasm, distinguished from other ovarian stromal tumors by the production of collagen and a pseudolobular pattern, and it tends to occur in the second and third decades of life in diagnosed patients. We discovered two rare cases of SST in post-menopausal women which are the topic of this report. These case studies are accompanied by a brief review of the literature.
		                        		
		                        		
		                        		
		                        			Collagen
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Menopause
		                        			;
		                        		
		                        			Ovarian Neoplasms
		                        			;
		                        		
		                        			Ovary*
		                        			;
		                        		
		                        			Sex Cord-Gonadal Stromal Tumors
		                        			
		                        		
		                        	
9.An association between preoperative anemia and poor prognostic factors and decreased survival in early stage cervical cancer patients.
Soyi LIM ; Chae Min LEE ; Jong Min PARK ; Sun Young JUNG ; Kwang Beom LEE
Obstetrics & Gynecology Science 2014;57(6):471-477
		                        		
		                        			
		                        			OBJECTIVE: To evaluate correlation of preoperative anemia with clinical outcomes in patients with early stage cervical cancer who were treated with radical hysterectomy and lymph node dissection. METHODS: Patients who underwent radical hysterectomy and lymph node dissection for cervical cancer from January 2001 to February 2012 were included in this study. Clinicopatholgoical factors included in univariate and multivariate analysis were age, tumor histology, FIGO (International Federation of Gyneocology and Obstetrics) stage, preoperative hemoglobin, depth of invasion, tumor size, parametrial involvement, resection margin, and lymph node status. RESULTS: A total of 387 patients were retrospectively analyzed in this study; 141 patients (36.4%) had preoperative anemia (hemoglobin <12 g/dL) and 16 out of 141 patients (11.3%) received blood transfusion for correction of preoperative anemia. Patients with preoperative anemia showed significant association with age <50 years, more advanced stage, non-squamous cell carcinoma histology, larger tumor size, deeper stromal invasion, and lymph node metastasis (P<0.05). Both relapse-free survival and overall survival were worse in patients with preoperative anemia in univariate analysis. In multivariate analysis, overall survival was worse in patients with preoperative anemia, but relapse-free survival was not associated with preoperative anemia. In the intergroup analysis of anemic patients for the effect of preoperative blood transfusion, preoperative anemia correction did not affect survival. CONCLUSION: Preoperative anemia was not an independent prognostic factor for survival in patients with early cervical cancer. However, it was associated with poor prognostic factors. Further study in large population is needed.
		                        		
		                        		
		                        		
		                        			Anemia*
		                        			;
		                        		
		                        			Blood Transfusion
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hysterectomy
		                        			;
		                        		
		                        			Lymph Node Excision
		                        			;
		                        		
		                        			Lymph Nodes
		                        			;
		                        		
		                        			Multivariate Analysis
		                        			;
		                        		
		                        			Neoplasm Metastasis
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Uterine Cervical Neoplasms*
		                        			
		                        		
		                        	
10.Peritoneal and Nodal Gliomatosis with Endometriosis, Accompanied with Ovarian Immature Teratoma: A Case Study and Literature Review.
Na Rae KIM ; Soyi LIM ; Juhyeon JEONG ; Hyun Yee CHO
Korean Journal of Pathology 2013;47(6):587-591
		                        		
		                        			
		                        			Gliomatosis peritonei (GP) indicates the peritoneal implantation of mature neuroglial tissue and is usually accompanied by ovarian mature or immature teratoma. Here, we report a case of ovarian immature teratoma associated with gliomatosis involving the peritoneum, lymph nodes and Douglas' pouch, where gliomatosis coexisted with endometriosis. As far as we know, only seven cases of GP have been reported as coexisting with endometriosis. Eight cases with mature glial tissue in the lymph nodes, i.e., nodal gliomatosis, have been published either in association with GP or in its absence. Metaplasia of pluripotent coelomic stem cells has been suggested to be responsible for the pathogenesis of endometriosis and GP rather than implantation metastases of ovarian teratomatous tumor with varying maturation. This theory is also applied to GP independently of ovarian teratomatous tumors. To the best of our knowledge, nodal gliomatosis coexisting with GP and also involving endometriosis has not yet been reported.
		                        		
		                        		
		                        		
		                        			Douglas' Pouch
		                        			;
		                        		
		                        			Endometriosis*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Lymph Nodes
		                        			;
		                        		
		                        			Metaplasia
		                        			;
		                        		
		                        			Neoplasm Metastasis
		                        			;
		                        		
		                        			Ovary
		                        			;
		                        		
		                        			Peritoneum
		                        			;
		                        		
		                        			Stem Cells
		                        			;
		                        		
		                        			Teratoma*
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail